Quantbot Technologies LP acquired a new stake in Laboratory Corporation of America Holdings (NYSE:LH) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 8,145 shares of the medical research company’s stock, valued at approximately $1,229,000.

A number of other large investors have also added to or reduced their stakes in LH. Janus Henderson Group PLC raised its stake in Laboratory Corporation of America Holdings by 5,992.1% in the second quarter. Janus Henderson Group PLC now owns 889,631 shares of the medical research company’s stock valued at $137,128,000 after buying an additional 875,028 shares during the period. Schroder Investment Management Group raised its stake in Laboratory Corporation of America Holdings by 1,337.1% in the second quarter. Schroder Investment Management Group now owns 860,802 shares of the medical research company’s stock valued at $130,885,000 after buying an additional 800,902 shares during the period. UBS Asset Management Americas Inc. raised its stake in Laboratory Corporation of America Holdings by 70.5% in the second quarter. UBS Asset Management Americas Inc. now owns 1,543,126 shares of the medical research company’s stock valued at $237,857,000 after buying an additional 637,848 shares during the period. Empyrean Capital Partners LP bought a new stake in Laboratory Corporation of America Holdings in the second quarter valued at approximately $92,484,000. Finally, Bessemer Group Inc. raised its stake in Laboratory Corporation of America Holdings by 43.6% in the second quarter. Bessemer Group Inc. now owns 1,288,017 shares of the medical research company’s stock valued at $198,535,000 after buying an additional 391,145 shares during the period. Hedge funds and other institutional investors own 92.96% of the company’s stock.

Laboratory Corporation of America Holdings (NYSE:LH) opened at $150.36 on Monday. Laboratory Corporation of America Holdings has a 52 week low of $123.36 and a 52 week high of $164.22. The company has a debt-to-equity ratio of 1.18, a quick ratio of 1.75 and a current ratio of 1.89. The company has a market capitalization of $15,400.00, a price-to-earnings ratio of 16.17, a price-to-earnings-growth ratio of 1.59 and a beta of 0.87.

Laboratory Corporation of America Holdings (NYSE:LH) last posted its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.46 EPS for the quarter, topping the Zacks’ consensus estimate of $2.38 by $0.08. Laboratory Corporation of America Holdings had a return on equity of 16.75% and a net margin of 7.40%. The firm had revenue of $2.60 billion for the quarter, compared to analyst estimates of $2.55 billion. During the same quarter last year, the company earned $2.25 EPS. The company’s revenue was up 9.5% on a year-over-year basis. equities analysts forecast that Laboratory Corporation of America Holdings will post 9.53 earnings per share for the current year.

WARNING: “Quantbot Technologies LP Acquires New Position in Laboratory Corporation of America Holdings (LH)” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/11/20/quantbot-technologies-lp-acquires-new-position-in-laboratory-corporation-of-america-holdings-lh.html.

A number of equities analysts have recently weighed in on LH shares. Craig Hallum reiterated a “buy” rating and set a $179.00 target price (up previously from $157.00) on shares of Laboratory Corporation of America Holdings in a research note on Thursday, July 27th. Zacks Investment Research upgraded Laboratory Corporation of America Holdings from a “sell” rating to a “hold” rating in a research note on Thursday, July 27th. Barclays PLC increased their target price on Laboratory Corporation of America Holdings from $182.00 to $183.00 and gave the stock an “overweight” rating in a research note on Thursday, July 27th. Morgan Stanley increased their target price on Laboratory Corporation of America Holdings from $154.00 to $166.00 and gave the stock an “overweight” rating in a research note on Thursday, August 10th. Finally, ValuEngine upgraded Laboratory Corporation of America Holdings from a “hold” rating to a “buy” rating in a research note on Wednesday, September 6th. Seven equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Laboratory Corporation of America Holdings has a consensus rating of “Buy” and a consensus price target of $169.00.

In other Laboratory Corporation of America Holdings news, CEO David P. King sold 132,713 shares of the firm’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $157.06, for a total value of $20,843,903.78. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider F Samuel Eberts III sold 31,500 shares of the firm’s stock in a transaction on Friday, August 25th. The shares were sold at an average price of $155.22, for a total value of $4,889,430.00. Following the completion of the sale, the insider now directly owns 31,894 shares in the company, valued at approximately $4,950,586.68. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 209,871 shares of company stock worth $32,892,005. Corporate insiders own 0.90% of the company’s stock.

Laboratory Corporation of America Holdings Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Laboratory Corporation of America Holdings (NYSE:LH).

Institutional Ownership by Quarter for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Stock Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related stocks with our FREE daily email newsletter.